CSIMarket Company Name, Ticker, Competitors, else..


Journey Medical Corp  (NASDAQ: DERM)
Other Ticker:  
 


 

Journey Medical Corp

DERM's Financial Statements and Analysis



Journey Medical Corp reported in the forth quarter of 2024 net earnings per share of $0.07 an improvement compare to net loss per share of $-0.11 recorded a year ago and an improvement compare to net loss per share of $-0.12 realized in previous quarter.


forth quarter of 2024
Earnings Per Share Revenues
$ 0.07 $  14 Mill
$+0.18     $-2M     -10.73 %



Journey Medical's Revenue fell by -10.73 % in forth quarter of 2024 (Dec 31 2024) year on year, to $14 million and declined by -6.9 % sequentially.


Journey Medical is

More on DERM's Income Statement



Journey Medical 's net income of $1.521 million in the forth quarter of 2024 increased from net loss of $-2.143 million IV. Quarter a year ago.

Sequentially Company turn into Profitability from net loss of $-2.390 million recorded in previous quarter.

More on DERM's Growth

Journey Medical Inventories
Inventories grew by 41.4 % to $14 million from IV. Quarter a year ago, sequentially inventories rose by 22.42 %. In Dec 31 2024 company's net cash and cash equivalents decreased by $-2 million

More on DERM's Cash flow Statement


Journey Medical Corp does not pay out common stock dividend.

In trailing twelve-month period Journey Medical Corp payed $ -0.45 cash per share, on a free-cash flow basis .

Book value grew by 85.12 % sequentially to $0.98 per share.
Tangible Book value fell to $ -0.58 per share from $ -0.34.

Company repurchased 0.16 million shares or 0.78 % in Dec 31 2024.


• More on DERM's Dividends

 Market Capitalization (Millions) 164
 Shares Outstanding (Millions) 20
 Total Debt (Millions $) 25
 Revenue (TTM) (Millions $) 56
 Net Income (TTM) (Millions $) -15
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) -15
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 19




Journey Medical Corp does not pay out common stock dividend.

In trailing twelve-month period Journey Medical Corp had negative $ -0.45 cash flow per share, on a free-cash flow basis .

Book value grew by 85.12 % sequentially to $0.98 per share.
Tangible Book value fell to $ -0.58 per share from $ -0.34.

Company repurchased 0.16 million shares or 0.78 % in Dec 31 2024.


• More on DERM's Balance Sheets

 Market Capitalization (Millions) 164
 Shares Outstanding (Millions) 20
 Total Debt (Millions $) 25
 Revenue (TTM) (Millions $) 56
 Net Income (TTM) (Millions $) -15
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) -15
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 19
   


  News about Journey Medical Corp Earnings

Deficit Despite Revenue Surge in the Fiscal Year Ending March 31 2024

Journey Medical Corporation, a pharmaceutical company focused on dermatological treatments, is making significant strides in the industry. Recently, the company presented data from a Phase 1 clinical trial at the 2024 American Academy of Dermatology Annual Meeting, showcasing the impact of their flagship product, DFD-29, on the microbial flora of healthy adults. This accomplishment highlights the company's commitment to advancing dermatological care and its importance within the dermatology community.
Additionally, the company's President and CEO, Claude Maraoui, will be presenting a corporate overview at the Planet MicroCap Showcase in Las Vegas. This event provides a platform for Journey Medical to sho...

Journey Medical Corporation Reports a Shortfall of $-0.11 per Share in Fiscal Period

Journey Medical Corporation is a cutting-edge pharmaceutical company that focuses on developing innovative treatments for various dermatological conditions. The company recently made headlines with the presentation of data from a Phase 1 clinical trial assessing the impact of their flagship product, DFD-29, on the microbial flora of healthy adults. This milestone was shared at the prestigious 2024 American Academy of Dermatology (AAD) Annual Meeting, showcasing the company's commitment to advancing dermatological research and treatment options.
The Phase 1 clinical trial aimed to evaluate the impact of DFD-29, a modified release capsule containing 40 mg of Minocycline Hydrochloride, on the microbial flor...

Journey Medical Corporation Surpasses Expectations with an Astounding 114.315% Revenue Growth in Q3 2023



In the bustling world of the stock market, there are always companies that manage to surprise investors with their performance. Journey Medical Corporation, a major player in the pharmaceutical preparations industry, recently reported a strong revenue advance of 114.315% year on year to $34.54 million during its July to September 30, 2023, time frame. However, what truly caught investors' attention was the company's remarkable turnaround to profitability, exhibiting earnings per share (EPS) at $0.80.
Pharmaceutical Preparations Industry
The overall performance of the Major Pharmaceutical Preparations sector has been less than stellar, experiencing a decline of -4.87% in revenue. This indust...

Journey Medical Corporation Reveals Slight Revenue Dip in Second Quarter of 2023

Journey Medical Corporation Faces Challenges but Shows Potential for Growth
In the fiscal timeframe of April to June 30, 2023, Journey Medical Corporation experienced a widening deficit of $-0.46 per share compared to $-0.43 per share the previous year. However, there is positive news as well, with the company's income per share improving from $-0.57 to $-0.43 per share during the same reporting season. Let's take a closer look at the financial performance of Journey Medical Corporation and analyze the factors that influenced its results.
One of the challenges faced by the company is a decrease in revenue by -6.118% to $17.17 million compared to $18.29 million in the corresponding reporting season la...


Date modified: 2025-03-27T19:21:46+00:00





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright � 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com